Summary & Overview
HCPCS J7208: Factor VIII, Recombinant Pegylated (Jivi), Injection
HCPCS Level II code J7208 denotes the injectable recombinant factor VIII product pegylated-aucl (brand name Jivi), billed per international unit for replacement therapy in hemophilia A. This biologic therapy is a high-cost specialty infusion medication with significant implications for coverage, site-of-care decisions, and utilization management nationwide. Payers commonly employ prior authorization, step therapy, and medical benefit policies to manage access and spending for factor VIII products.
Key payers evaluated include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of national coverage considerations, typical sites of service where J7208 is administered, and the clinical context for use in hemophilia A. The publication also summarizes benchmarking topics relevant to hospital and outpatient infusion settings, identifies common billing modifiers used with specialty injectables, and highlights policy elements that affect reimbursement and claim processing.
This summary provides clinicians, billing professionals, and policy analysts with concise context on what J7208 represents, why it matters in specialty pharmacy and infusion services, and which payers and policy levers most commonly influence access and payment for this therapy.
Billing Code Overview
HCPCS Level II code J7208 represents an injection of factor VIII — specifically antihemophilic factor, recombinant, pegylated-aucl (Jivi) — billed per 1 international unit (i.u.). This product is a long-acting recombinant factor VIII concentrate indicated for replacement therapy in patients with hemophilia A.
Service Type: Injectable factor replacement therapy
Typical Site of Service: Hospital outpatient infusion center, ambulatory infusion clinic, or outpatient specialty infusion center
Clinical & Coding Specifications
Clinical Context
A 28-year-old male with severe hemophilia A presents to an ambulatory infusion center for routine prophylactic factor VIII replacement with pegylated recombinant antihemophilic factor (J7208). The patient has a history of spontaneous joint bleeding and uses factor VIII prophylaxis on a fixed schedule every 5–7 days. Before the infusion, a nurse verifies identity, reviews the most recent weight and prior dose, confirms venous access (peripheral IV or port), inspects the product vial and lot number, and documents the lot and expiration date. The pharmacy prepares a patient-specific dose measured in International Units (IU) and labels syringes. The infusion nurse administers the reconstituted product per manufacturer instructions, monitors for infusion reactions for 30–60 minutes post-infusion, and documents start/stop times, lot number, dose in IU, and any adverse events in the electronic medical record. Typical sites of service include hospital outpatient infusion centers, freestanding infusion clinics, and occasionally home health infusion by a trained RN. Common clinical workflow steps include physician prescription/order, pharmacist verification and compounding, nursing administration, and post-infusion documentation and billing of J7208 per IU administered.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered |